Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels

In this study, we compared entecavir and tenofovir alafenamide in terms of their ability to reduce hepatitis B surface antigen (HBsAg) in the same group of patients with HBV infection. Methods: During March and June 2018, 129 patients who received entecavir were switched to tenofovir alafenamide. Every 3– 6 months for 1 year before and after switching to tenofovir alafenamide, all patients underwent measurements of HBsAg, hepatitis core-related antigen (HBcrAg), calcium (Ca), inorganic phosphorus, and estimated glomerular filtration rate (eGFR). Results: The percent decline rate during the entecavir and tenofovir alafenamide phases at 6 months were 2.38% (−3.57 to 0.00) and −3.57% (−7.14 to 0.00), respectively, and those at 12 months were 3.03% (−6.57 to 0.00) and −5.56% (−7.41 to −2.50), respectively. HBsAg levels were reduced significantly more during the tenofovir alafenamide phase than during the entecavir phase (P 
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research